Clarivate Names Orforglipron and Retatrutide as Defining GLP-1 Drugs of the Next Decade
Clarivate projects orforglipron and retatrutide as the defining GLP-1 drugs of the next decade. Retatrutide is projected for 2028 launch after seven additional Phase III readouts expected this year.